Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Trodelvy gets one up on Datroway in triple-negative breast
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
